İki uçlu duygudurum bozukluğu ve osteomalazisi olan hastada akut dönem ve koruma tedavisi nasıl yapılmalı? Bir olgu sunumu

iki uçlu duygudurum bozukluğu manik dönem tanısıyla servise yatırılan hastaya, osteomalazi ikincil hiperparatroidi ve çölyak hastalığı tanısı da konuldu. Osteomalazinin etiyolojisinde lityum, karbamazepin, valproik asit ve antipsikotikler de sorumlu bulunmuştur. Bizim vakamızda osteomalazinin sebebi bu ilaçlar olmadığı düşünülmesine rağmen osteomalazinin varlığında manik atağın nasıl tedavi edileceği ve koruyucu tedavinin nasıl yapılacağı problem olmuştur. Sunduğumuz olgu dolayısıyla tedavi stratejisindeki bu zorluk tartışılmıştır.

How can we treat the patient with bipolar disorder and osteomalacia in acute phase and do prophylaxis? A case report

The patient who was hospitalized with bipolar disorder in manic episode had also diagnoses of osteomalacia, secondary hyperparathyrodism and celiac disease. Lithium, carbamazepine, valproic acid and neuroleptics that are used for treatment and prophylaxis of bipolar disorders may lead to osteoporosis and osteomalacia. In our case, although it was thought that the reason for osteomalacia is not these medications, the treatment in manic episode and prophylaxis of bipolar disorder became a problem in the presence of osteomalacia. In this case report, the difficulties in treatment strategy were discussed.

___

  • 1. Tannirandorn P, Epstein S: Drug-induced bone loss. Osteoporos Int 2000; 11:637-659.
  • 2. Ray JG, Papaioannou A, Ioannidis G, Adachi JD: Anticonvulsant drug use and low bone mass in adults with neurodevelopmental disorders. Q J Med 2002; 95:219-223.
  • 3. Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF ve ark: Antiepileptic druginduced bone loss in young male patients who have seizures. Arch Neurol 2002; 9:781-786.
  • 4. Naidoo U, Goff DC, Klibanski A: Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28:97-108.
  • 5. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M Tan U: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002; 112:817-828.
  • 6. Pedrera JD, Canal ML, Carvajal J, Postigo S, Villa LF, Hernandez ER ve ark: Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000; 30:895-899.
  • 7. Leutgeb U: Lithium and its effects on the endocrine system, bones and peripheral nerves-a current review. Fortschr Neurol Psychiatr 1995; 63:149-161.
  • 8. Gönül AS: Özel gruplar ve durumlarda sağaltım, bedensel hastalıklar. S Vahip, O Yazıcı (eds): İki Uçlu Duygudurum Bozuklukları Sağaltım Kılavuzu’nda. İstanbul, Türkiye Psikiyatri Derneği Yayınları, 2003, s.155-164.
  • 9. Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME ve ark: Practice Guidelines for the Treatment of Psychiatric Disorders. Washington DC, American Psychiatric Association, 2002, s.547-634.
  • 10. Corazza GR, Di Sario A, Cecchetti L, Terazzi C, Corrao G, Bernardi M ve ark: Bone mass and metabolism in patients with celiac disease. Gastroenterology 1995; 109:122-128.
  • 11. Kemppainen T, Kroger H, Janatuinen E, Arnaha I, Kosma VM, Pikkarainen P ve ark: Osteoporosis in adult with celiac disease. Bone 1999; 24:249-255.
  • 12. Vasquez H, Mazure R, Gonzalez D, Flores D, Pedreira S, Niveloni S ve ark: Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol 2000; 95:183-189.
  • 13. Farell RJ, Kelly CP: Diagnosis of Celiac Sprue. Am J Gastroenterol 2001; 96:3237-3246.
  • 14. Maki M: The humoral immune system in celiac disease. Baillieres Clin Gastroenterol 1995; 9:231-249.
  • 15. Lambert MT, Bjarnason I, Connelly J, Crow TJ, Johnstone EC, Peters TJ ve ark: Small intestine permeability in schizophrenia. Br J Psychiatry 1989; 155:619-622.
  • 16. Özkan S: Psikiyatrik Tıp. Konsültasyon ve Liyezon Psikiyatrisi. İstanbul, Roche Müstahzarları, 1993.
  • 17. Kusalic M, Engelsmann F: Effect of lithium maintenance therapy on thyroid and parathyroid function. J Psychiatry Neurosci 1999; 24:227-233.
  • 18. Haden ST, Stoll AL, Mccormick S, Scott J, Fuleihan GE: Alterations in parathyroid dynamics in lithium treated subjects. J Clin Endocrinol Metab 1997; 82:2844-2848.
  • 19. Rifai MA, Moles JK, Harrington DP: Lithium-induced hypercalcemia and parathyroid dysfunction. Psychosomatics 2001; 42:359-361.
  • 20. Becker D, Liver O, Master R, Rapoport M, Weizman A, Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64:761-766.
  • 21. Drenth JPH, Pieters GFFM, Hermus ARMM: Epilepsy, broken bones, and fatty stools. The Lancet 2000; 355:1882.